Investors Optimistic On FDA Panel For Novo’s Insulin Degludec
This article was originally published in The Pink Sheet Daily
Investors appear upbeat about a Nov. 8 FDA advisory committee on Novo Nordisk’s next-generation insulin degludec (Tresiba), despite some concerns on the cardiovascular safety front.
You may also be interested in...
Europe’s top drug advisory panel, CHMP, gave backing to Novo Nordisk’s new long-acting insulin analog as well as to new therapies from Astellas and Savient for urinary incontinence and severe gout.
FDA’s advisory committee meeting on Nov. 8 falls just after the already-extended user fee date for Novo Nordisk’s long-acting insulin degludec and degludec/insulin aspart.
Companies presented data at ADA that could give patients options other than Lantus, but Sanofi is fighting back with a strategy to retain them.